Insilico Medicine and Tenacia Biotechnology expand CNS R&D collaboration, with a total value of up to 947.5 million US dollars

Insilico Medicine (3696.HK), a clinical-stage biopharmaceutical company powered by generative artificial intelligence,andTenacia Biotechnology, a company focused on the development and commercialization of central nervous system (CNS) drugs,announced today that, building on a strong collaborative relationship over the past year, both parties will further expand and deepen their AI-driven drug discovery partnership.

In their collaborationreached in March 2025,Insilico Medicine leveraged its cutting-edge generative artificial intelligence drug discovery platform, Pharma.AI, along with extensive R&D experience, while Tenacia Biotechnology contributed its specialized research achievements and proprietary data assets. The focus was on developing small molecule inhibitors with the potential to penetrate the blood-brain barrier (BBB). This collaboration is proceeding as planned.

This extended collaborationThe two parties will leverage generative AI to jointly develop an innovative candidate molecule with specific attributes for challenging neurological diseasesand advance it to the preclinical candidate drug (PCC) stage to meet differentiated clinical needs. By exploring strategies with different molecular characteristics, both parties aim to provide broader and more precise treatment options for highly challenging neurological diseases, thereby reducing late-stage R&D risks and enhancing potential clinical benefits. The total transaction amount of this expanded collaborationcan reach up to 94.75 million US dollars at its highest.Insilico Medicine is expected to receive near-term payments and milestone-based payments from Yuan Yi Bio.

Dr. Alex Zhavoronkov, founder and CEO of Insilico Medicine, stated,"The rapid initiation of a second R&D project with differentiated attributes around the same target in such a short period fully demonstrates the depth and flexibility of generative AI in drug design. The deep integration of Yuan Yi Bio's extensive expertise in CNS and the Pharma.AI platform continues to generate innovative solutions with high clinical translational value. We are very pleased to further deepen our strategic cooperation with Yuan Yi Bio and look forward to continuing to work together using advanced AI technology to break through neuroscience R&D bottlenecks, accelerate transformative therapies, and benefit patients worldwide."

Yuan Yi Bio stated,"Yuan Yi Bio focuses on drug discovery and development for neurological diseases and is committed to bringing innovative and differentiated treatment options to patients. Our ongoing collaboration with Insilico Medicine has witnessed significant innovative progress based on each party's strengths. We are very excited to see that the further expanded cooperation will bring even more valuable drug candidates."

In recent years, relying on artificial intelligence platforms and deep understanding of disease mechanisms, Insilico Medicine has continued to strengthen and expand its presence in the central nervous system (CNS) disease field. In early 2026, Insilico Medicine’s joint venture with Fosun Pharma, Heng Tai Bio,reached a co-development agreement on the NLRP3-targeted candidate molecule ISM8969., with both parties holding 50% of the global rights to the project; meanwhile, Insilico Medicine is entitled to receive upfront and milestone payments of over 500 million Hong Kong dollars. The project received FDA clinical trial approval in January 2026from the US FDA for the treatment of Parkinson's disease.

About Insilico Medicine

Insilico Medicine is a global pioneer biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery and drive innovation in the life sciences sector, enabling longer and healthier lives for humanity. On December 30, 2025, the company was listed on the Main Board of the Hong Kong Stock Exchange, with stock code: 03696.HK.

Using its self-developed Pharma.AI platform and advanced automated biology laboratories, Insilico Medicine is providing innovative drug solutions for unmet disease areas such as fibrosis, oncology, immunology, pain, obesity, and metabolic disorders. Additionally, Insilico Medicine continues to expand the application of Pharma.AI into diversified fields such as advanced materials, agriculture, nutritional products, and veterinary drugs. For more information, please visit www.insilico.com.

About MetaGenius Bio

MetaGenius Bio was founded in 2022 and is headquartered in Shanghai, China. It is a commercial-stage innovative biopharmaceutical company specializing in neuroscience. Backed by Bain Capital, MetaGenius Bio was co-founded by a senior professional team that combines international expertise with deep knowledge of China's biopharmaceutical ecosystem. Prioritizing patient needs, the company strategically partners with global ecosystem players to harness specialized capabilities and strengths in neuroscience. By driving the translation of cutting-edge technologies, it aims to provide first-in-class or best-in-class innovative solutions for patients in China and worldwide, significantly improving the quality of life for patients and their families.

11K Views